Juno Therapeutics Stops Trial Of Cancer-Killing Cells After 3 Patient Deaths

July 08, 2016 | Three patients have died in a closely watched study of using genetically engineered white blood cells to treat adult leukemia patients, forcing the trial to be put on hold. The news is a blow for Juno Therapeutics, the biotechnology startup valued at $4.3 billion. Forbes